Literature DB >> 31519498

Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma.

Stefanie N Meyer1, Claudio Scuoppo2, Sofija Vlasevska1, Elodie Bal1, Antony B Holmes1, Mara Holloman1, Laura Garcia-Ibanez1, Sarah Nataraj1, Romain Duval1, Thomas Vantrimpont1, Katia Basso2, Nigel Brooks3, Riccardo Dalla-Favera4, Laura Pasqualucci5.   

Abstract

Inactivating mutations of the CREBBP and EP300 acetyltransferases are among the most common genetic alterations in diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL). Here, we examined the relationship between these two enzymes in germinal center (GC) B cells, the normal counterpart of FL and DLBCL, and in lymphomagenesis by using conditional GC-directed deletion mouse models targeting Crebbp or Ep300. We found that CREBBP and EP300 modulate common as well as distinct transcriptional programs implicated in separate anatomic and functional GC compartments. Consistently, deletion of Ep300 but not Crebbp impaired the fitness of GC B cells in vivo. Combined loss of Crebbp and Ep300 completely abrogated GC formation, suggesting that these proteins partially compensate for each other through common transcriptional targets. This synthetic lethal interaction was retained in CREBBP-mutant DLBCL cells and could be pharmacologically targeted with selective small molecule inhibitors of CREBBP and EP300 function. These data provide proof-of-principle for the clinical development of EP300-specific inhibitors in FL and DLBCL.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CREBBP; EP300; acetyltransferase inhibitor; dark zone; diffuse large cell lymphoma; germinal center; light zone; synthetic lethality

Mesh:

Substances:

Year:  2019        PMID: 31519498     DOI: 10.1016/j.immuni.2019.08.006

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  37 in total

Review 1.  Treatment resistance in diffuse large B-cell lymphoma.

Authors:  Michael Y He; Robert Kridel
Journal:  Leukemia       Date:  2021-05-20       Impact factor: 11.528

2.  Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734.

Authors:  Filippo Spriano; Eugenio Gaudio; Luciano Cascione; Chiara Tarantelli; Federica Melle; Giovanna Motta; Valdemar Priebe; Andrea Rinaldi; Gaetanina Golino; Afua Adjeiwaa Mensah; Luca Aresu; Emanuele Zucca; Stefano Pileri; Michael Witcher; Bill Brown; Claes Wahlestedt; Francis Giles; Anastasios Stathis; Francesco Bertoni
Journal:  Blood Adv       Date:  2020-09-08

3.  Role of Systemic Lupus Erythematosus Risk Variants With Opposing Functional Effects as a Driver of Hypomorphic Expression of TNIP1 and Other Genes Within a Three-Dimensional Chromatin Network.

Authors:  Satish Pasula; Kandice L Tessneer; Yao Fu; Jaanam Gopalakrishnan; Richard C Pelikan; Jennifer A Kelly; Graham B Wiley; Mandi M Wiley; Patrick M Gaffney
Journal:  Arthritis Rheumatol       Date:  2020-03-30       Impact factor: 10.995

4.  Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study.

Authors:  Lan Zhang; Xingnong Ye; Shuna Luo; Xiaofei Xu; Shengjie Wang; Keyi Jin; Yan Zheng; Xiaoqiong Zhu; Dan Chen; Jie Jin; Jian Huang
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-22       Impact factor: 4.553

5.  Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.

Authors:  Dominik Nann; Joan Enric Ramis-Zaldivar; Inga Müller; Blanca Gonzalez-Farre; Janine Schmidt; Caoimhe Egan; Julia Salmeron-Villalobos; Guillem Clot; Sven Mattern; Franziska Otto; Barbara Mankel; Dolors Colomer; Olga Balagué; Vanessa Szablewski; Carmen Lome-Maldonado; Lorenzo Leoncini; Stefan Dojcinov; Andreas Chott; Christiane Copie-Bergman; Irina Bonzheim; Falko Fend; Elaine S Jaffe; Elias Campo; Itziar Salaverria; Leticia Quintanilla-Martinez
Journal:  Blood Adv       Date:  2020-11-24

6.  Harnessing lymphoma epigenetics to improve therapies.

Authors:  Haopeng Yang; Michael R Green
Journal:  Blood       Date:  2020-11-18       Impact factor: 22.113

7.  Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition.

Authors:  Simon J Hogg; Olga Motorna; Leonie A Cluse; Timothy M Johanson; Hannah D Coughlan; Ramya Raviram; Robert M Myers; Matteo Costacurta; Izabela Todorovski; Lizzy Pijpers; Stefan Bjelosevic; Tobias Williams; Shannon N Huskins; Conor J Kearney; Jennifer R Devlin; Zheng Fan; Jafar S Jabbari; Ben P Martin; Mohamed Fareh; Madison J Kelly; Daphné Dupéré-Richer; Jarrod J Sandow; Breon Feran; Deborah Knight; Tiffany Khong; Andrew Spencer; Simon J Harrison; Gareth Gregory; Vihandha O Wickramasinghe; Andrew I Webb; Phillippa C Taberlay; Kenneth D Bromberg; Albert Lai; Anthony T Papenfuss; Gordon K Smyth; Rhys S Allan; Jonathan D Licht; Dan A Landau; Omar Abdel-Wahab; Jake Shortt; Stephin J Vervoort; Ricky W Johnstone
Journal:  Mol Cell       Date:  2021-05-20       Impact factor: 17.970

Review 8.  The language of chromatin modification in human cancers.

Authors:  Shuai Zhao; C David Allis; Gang Greg Wang
Journal:  Nat Rev Cancer       Date:  2021-05-17       Impact factor: 60.716

9.  Multiregional Sequencing of IDH-WT Glioblastoma Reveals High Genetic Heterogeneity and a Dynamic Evolutionary History.

Authors:  Sara Franceschi; Prospero Civita; Francesco Pasqualetti; Francesca Lessi; Martina Modena; Serena Barachini; Mariangela Morelli; Orazio Santonocito; Riccardo Vannozzi; Geoffrey J Pilkington; Valerio Ortenzi; Antonio Giuseppe Naccarato; Paolo Aretini; Chiara Maria Mazzanti
Journal:  Cancers (Basel)       Date:  2021-04-23       Impact factor: 6.639

Review 10.  Biology of Germinal Center B Cells Relating to Lymphomagenesis.

Authors:  Katia Basso
Journal:  Hemasphere       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.